Emergence of mupirocin-resistant Staphylococcus aureus in chronic peritoneal dialysis patients using mupirocin prophylaxis to prevent exit-site infection

Peritoneal Dialysis International

Volumn 21, Issue 6, 2001, Pages 554-559

  Annigeri, Rajeev ^a   Conly, John ^a   Vas, Stephen I ^a   Dedier, Helen ^a   Prakashan, Kannam P ^a   Bargman, Joanne M ^a   Jassal, Vanita ^a   Oreopoulos, Dimitrios ^a  

^a TORONTO WESTERN HOSPITAL   (Canada)

Author keywords

Chronic peritoneal dialysis; Mupirocin prophylaxis; Mupirocin resistant Staphylococcus aureus

Indexed keywords

AGAR; MANNITOL; METICILLIN; OXACILLIN; PSEUDOMONIC ACID;

ADULT; AGED; ANTIBIOTIC PROPHYLAXIS; ANTIBIOTIC RESISTANCE; ARTICLE; AXILLA; BACTERIUM CARRIER; BACTERIUM CULTURE; BACTERIUM ISOLATE; BACTERIUM ISOLATION; CLINICAL PRACTICE; CONTROLLED STUDY; DRUG USE; FEMALE; HUMAN; HUMAN TISSUE; INGUINAL REGION; KIDNEY FAILURE; MAJOR CLINICAL STUDY; MALE; METHICILLIN RESISTANT STAPHYLOCOCCUS AUREUS; MINIMUM INHIBITORY CONCENTRATION; NOSE SMEAR; PERITONEAL DIALYSIS; PERITONITIS; PREVALENCE; PRIORITY JOURNAL; SCREENING TEST; STAPHYLOCOCCUS AUREUS; STAPHYLOCOCCUS INFECTION; TREATMENT FAILURE;

EID: 0035701820     PISSN: 08968608     EISSN: None     Source Type: Journal    
DOI: 10.1177/089686080102100604     Document Type: Article

References (38)

1. Staphylococcus aureus infections in dialysis patients: Focus on prevention
2. Staphylococcus aureus carriage and infections in patients on continuous ambulatory dialysis
3. Nasal mupirocin prevents Staphylococcus aureus exit-site infection during peritoneal dialysis
4. Randomized controlled trial of prophylactic rifampin for peritoneal dialysis-related infections
5. Decrease in Staphylococcus aureus exit-site infections and peritonitis in CAPD patients by local application of mupirocin ointment at the catheter exit site
6. A randomized trial of Staphylococcus aureus prophylaxis in peritoneal dialysis patients: Mupirocin calcium ointment 2% applied to the exit site versus cyclic oral rifampin
7. Application of mupirocin cream at the catheter exit site reduces exit-site infections and peritonitis in peritoneal dialysis patients
8. Staphylococcal peritonitis in continuous ambulatory peritoneal dialysis: Colonization with identical strains at exit site, nose and hands
9. Methicillin-resistant Staphylococcus aureus in Ontario
10. The epidemiology of mupirocin resistance among methicillin-resistant Staphylococcus aureus at a Veterans' Affairs Hospital
11. The prevalence of low- and high-level mupirocin resistance in staphylococci from 19 European hospitals
12. Emergence of high-level mupirocin resistance in methicillin-resistant Staphylococcus aureus isolated from Brazilian university hospitals
13. Development of mupirocin resistance among methicillin-resistant Staphylococcus aureus after widespread use of nasal mupirocin ointment
14. Emergence and spread of low-level mupirocin resistance in methicillin-resistant Staphylococcus aureus isolated from a community hospital in Japan
15. Resistance to mupirocin: No indication of it to date while using mupirocin ointment for prevention of Staphylococcus aureus exit-site infections in peritoneal dialysis patients
16. Increasing resistance to mupirocin of Staphylococcus aureus (S Au) strains isolated from peritoneal dialysis (PD) patients and their partners: Long term study
17. Interpretive criteria for disk diffusion susceptibility testing of mupirocin, a topical antibiotic
18. Evaluation of disc diffusion and E test for determining the susceptibility of Staphylococcus aureus to mupirocin
19. The emergence of mupirocin resistance: A challenge to infection control and antibiotic prescribing practice
20. Antiseptic resistance in methicillin-resistant Staphylococcus aureus: An emerging problem
21. Mupirocin-resistant Staphylococcus aureus
22. Mupirocin-resistant Staphylococcus aureus
23. Mupirocin-resistant methicillin-resistant Staphylococcus aureus in Western Australia
24. Mupirocin resistance and methicillin-resistant Staphylococcus aureus (MRSA)
25. The efficacy of calcium mupirocin in the eradication of nasal Staphylococcus aureus carriage
26. Molecular characterization and transfer among Staphylococcus strains of a plasmid conferring high-level resistance to mupirocin
27. Staphylococcus aureus nasal carriage, exit-site infection and catheter loss in patients treated with continuous ambulatory peritoneal dialysis (CAPD)
28. Lack of correlation between nasal cultures positive for Staphylococcus aureus and the development of S. aureus exit-site infections: Results unaffected by routine mupirocin treatment of nasal S. aureus carriage
29. Treatment of Staphylococcus aureus nasal carriers in CAPD with mupirocin
30. Staphylococcus aureus carriage and infections among patients in four haemo- and peritoneal-dialysis centers in Denmark
31. New strategies to prevent Staphylococcus aureus infections in peritoneal dialysis patients
32. Natural history of Staphylococcus aureus nasal carriage and its relation to exit-site infection
33. The utility of polysporin ointment in the eradication of methicillin-resistant Staphylococcus aureus colonization: A pilot study
34. Susceptibility of methicillin-resistant Staphylococcus aureus to the essential oil of Melaleuca alternifolia
35. The in-vitro activity of povidone-iodine cream against Staphylococcus aureus and its bioavailability in nasal secretions
36. Comparison of the in-vitro activities of the topical antimicrobials azelaic acid, nitrofurazone, silver sulphadiazine and mupirocin against Staphylococcus aureus
37. Control of an outbreak of an epidemic methicillin-resistant Staphylococcus aureus also resistant to mupirocin
38. Cost-effectiveness of prophylactic nasal mupirocin in patients undergoing peritoneal dialysis based on a randomized, placebo-controlled trial